{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:20:10Z","timestamp":1774736410129,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/md.0000000000000540","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T21:48:21Z","timestamp":1424900901000},"page":"e540","source":"Crossref","is-referenced-by-count":11,"title":["High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer"],"prefix":"10.1097","volume":"94","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210309","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014.","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R2-4-20210309","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.2006.07.2983","article-title":"Lung cancer incidence in never smokers.","volume":"25","author":"Wakelee","year":"2007","journal-title":"J Clin Oncol"},{"key":"R3-4-20210309","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1378\/chest.123.6.1868","article-title":"Clinical characteristics of pneumonic-type adenocarcinoma of the lung.","volume":"123","author":"Wislez","year":"2003","journal-title":"Chest"},{"key":"R4-4-20210309","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1556-0864(15)31593-8","article-title":"The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases.","volume":"1","author":"Garfield","year":"2006","journal-title":"J Thorac Oncol"},{"key":"R5-4-20210309","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-4-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"R7-4-20210309","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R8-4-20210309","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R9-4-20210309","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/JTO.0000000000000022","article-title":"Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.","volume":"9","author":"Nakamura","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R10-4-20210309","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0b013e31823e5e2d","article-title":"Objective review of mediastinal lymph node examination in a lung cancer resection cohort.","volume":"7","author":"Osarogiagbon","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R11-4-20210309","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung CancerAmerican Thoracic SocietyEuropean Respiratory Society international multidisciplinary classification of lung adenocarcinoma.","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R12-4-20210309","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res"},{"key":"R13-4-20210309","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","article-title":"Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.","volume":"2","author":"Dias-Santagata","year":"2010","journal-title":"EMBO Mol Med"},{"key":"R15-4-20210309","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1259\/bjr.74.882.740490","article-title":"CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia.","volume":"74","author":"Jung","year":"2001","journal-title":"Br J Radiol"},{"key":"R17-4-20210309","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.athoracsur.2014.04.108","article-title":"The correlation of the International Association for the Study of Lung Cancer (IASLC)American Thoracic Society (ATS)European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.","volume":"98","author":"Yanagawa","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"R18-4-20210309","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1378\/chest.114.1.45","article-title":"Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors.","volume":"114","author":"Regnard","year":"1998","journal-title":"Chest"},{"key":"R19-4-20210309","first-page":"1349","article-title":"Bronchioloalveolar carcinoma masquerading as pneumonia.","volume":"49","author":"Thompson","year":"2004","journal-title":"Respir Care"},{"key":"R20-4-20210309","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3892\/ol.2014.2160","article-title":"Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression.","volume":"8","author":"Pan","year":"2014","journal-title":"Oncol Lett"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:41:22Z","timestamp":1620960082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201502040-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000540","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}